HIMS, CRWV, and CAVA Report This Week: What to Expect

Three names are dominating the finance corner of YouTube and X this week, and for once, none of them are Nvidia. $HIMS, $CRWV, and $CAVA all report earnings in the next few days, and the sentiment around each one tells a completely different story.

Start with $HIMS (Hims and Hers), which reports Monday after close. Bloomberg Podcasts flagged the core problem clearly: subscriber growth has cratered from 35% over 16 quarters to somewhere between 9% and 13% in recent periods. The company is also staring down an FTC lawsuit alleging misleading subscription practices and privacy violations. The one potential bright spot is a new AI-native doctor-led care app launched just before earnings, which could help with churn. But the stock is already down roughly 9% this quarter, so the bar is low and the overhang is real. X sentiment is cautious to bearish, with most retail chatter focused on whether the GLP-1 adjacency narrative still holds water post-FDA clarification.

Then there is $CRWV (CoreWeave), reporting Tuesday after close. Bloomberg Intelligence expects revenue of around $2.5 billion, which would be the highest print since the company's 2025 IPO. YouTube finance channels are notably bullish here, with the AI infrastructure thesis still intact and hyperscaler demand holding up better than bears expected. The bear case is valuation: this stock priced into a world where AI capex never slows, and Andrei Jikh's recent video on the AI bubble explicitly named a scenario where one major hyperscaler pulls back and triggers a cascade. CoreWeave would not be immune to that. Watch the guidance commentary more than the headline number.

Finally, $CAVA rounds out the week, and honestly its situation is the most interesting because it is the least its own fault. Bloomberg's restaurant coverage this week zeroed in on the Cyclospora parasite outbreak linked to Taylor Farms iceberg lettuce, which has spooked consumers away from anything leafy. Cava does not serve iceberg lettuce, but Sweetgreen already cut its full-year same-store sales outlook from a 4% decline to as much as an 8% decline on knock-on effects alone. Cava is a stronger concept with better unit economics than Sweetgreen, but fear is not rational and foot traffic does not discriminate.

The macro backdrop for all three is a market with zero reliable index data this session and a Middle East geopolitical situation that is keeping energy traders, not tech investors, up at night. That actually gives these three earnings reports more oxygen than usual: when the tape has nothing to anchor to, individual stock stories dominate the conversation.

Three companies, three completely different problems, and one week to find out which story the market actually believes.